21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer - PubMed (original) (raw)
21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer
Charles E Geyer Jr et al. NPJ Breast Cancer. 2018.
Abstract
The NSABP B-20 prospective-retrospective study of the 21-gene Oncotype DX Breast Cancer Recurrence Score® test predicted benefit from addition of chemotherapy to tamoxifen in node-negative, estrogen-receptor positive breast cancer when recurrence score (RS) was ≥31. HER2 is a component of the RS algorithm with a positive coefficient and contributes to higher RS values. Accrual to B-20 occurred prior to routine testing for HER2, so questions have arisen regarding assay performance if HER2-positive patients were identified and excluded. We report an exploratory reanalysis of the B-20, 21-gene study following exclusion of such patients. Patients were considered HER2 positive if quantitative RT-PCR for HER2 was ≥11.5 units, and excluded from re-analyses performed using the original cutoffs: <18, 18-30, ≥31, and the TAILORx cutoffs: <11, 11-25, >25. The endpoint remained distant recurrence-free interval (DRFI) as in the original study. Distribution was estimated via the Kaplan-Meier method and compared via log-rank test. Multivariate Cox proportional hazards models estimated chemotherapy benefit in each group. In the RS < 18 and 18-30 groups, 1.7 and 6.7% were HER2 positive. In the RS ≥ 31 group, 41% were HER2 positive. Exclusion resulted in fewer events, with loss of significance for benefit from chemotherapy in the overall HER2-negative cohort (log-rank _P_ = 0.06), but substantial benefit from chemotherapy remained in the RS ≥ 31 cohort (HR = 0.18; 95% CI: 0.07-0.47) and the RS > 25 cohort (HR = 0.28; 95% CI: 0.12-0.64). No benefit from chemotherapy was evident in the other RS groups. Following exclusion of HER2-positive patients based on RT-PCR expression, substantial benefit of chemotherapy remained for RS ≥ 31 as originally employed, and with RS > 25 employed in TAILORx.
Conflict of interest statement
Dr. Mamounas: Genomic Health, Inc.: Consultant, Honoraria (Speaker); Biotheranostics: Consultant. Dr. Paik discloses being listed as one of the inventors of OncotypeDx in the patents, but all rights have been transferred to NSABP Foundation, resulting in no financial interest. Dr. Shak: Genomic Health, Inc.: Full-time employee and shareholder. Dr. Crager: Employment at Genomic Health, Inc., and ownership of company stock. Dr. Baehner: Employee and minor shareholder of Genomic Health, Inc. All other authors declare no other potential competing interest(s).
Figures
Fig. 1
CONSORT Diagram for 21-gene assay study using available primary breast cancer specimens from NSABP B-20
Fig. 2
Kaplan–Meier estimates of the probability of remaining free of distant recurrence by original RS groups following exclusion of patients with presumed HER2-positive disease, comparing treatment with tamoxifen alone with tamoxifen plus chemotherapy. a All patients; b low-risk RS < 18; c intermediate-risk RS 18–30; and d high-risk RS ≥ 31
Fig. 3
Kaplan–Meier estimates of the probability of remaining free of distant recurrence by TAILORx RS groups following exclusion of patients with presumed HER2-positive disease comparing treatment with tamoxifen alone with tamoxifen plus chemotherapy. a RS < 11; **b** RS 11–25; **c** RS > 25
Similar articles
- Impact of TAILORx on chemotherapy prescribing and 21-gene recurrence score-guided treatment costs in a population-based cohort of patients with breast cancer.
Tesch ME, Speers C, Diocee RM, Gondara L, Peacock SJ, Nichol A, Lohrisch CA. Tesch ME, et al. Cancer. 2022 Feb 15;128(4):665-674. doi: 10.1002/cncr.33982. Epub 2021 Dec 2. Cancer. 2022. PMID: 34855202 - Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
Lee SH, Ha S, An HJ, Lee JS, Han W, Im SA, Ryu HS, Kim WH, Chang JM, Cho N, Moon WK, Cheon GJ. Lee SH, et al. Eur J Nucl Med Mol Imaging. 2016 Aug;43(9):1574-84. doi: 10.1007/s00259-016-3418-1. Epub 2016 May 21. Eur J Nucl Med Mol Imaging. 2016. PMID: 27209424 - Clinical relevance of the 21-gene Recurrence Score® assay in treatment decisions for patients with node-positive breast cancer in the genomic era.
Mamounas EP, Russell CA, Lau A, Turner MP, Albain KS. Mamounas EP, et al. NPJ Breast Cancer. 2018 Aug 20;4:27. doi: 10.1038/s41523-018-0082-6. eCollection 2018. NPJ Breast Cancer. 2018. PMID: 30155517 Free PMC article. Review. - Controversies and Opportunities in the Clinical Daily Use of the 21-Gene Assay for Prognostication and Prediction of Chemotherapy Benefit in HR+/HER2- Early Breast Cancer.
Jacobs F, Gaudio M, Benvenuti C, De Sanctis R, Santoro A, Zambelli A. Jacobs F, et al. Cancers (Basel). 2022 Dec 27;15(1):148. doi: 10.3390/cancers15010148. Cancers (Basel). 2022. PMID: 36612144 Free PMC article. Review.
Cited by
- Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study.
Guerrero-Zotano Á, Pérez-García JM, Ruiz-Borrego M, Bermejo B, Gil-Gil M, de la Haba J, Alba Conejo E, Quiroga V, Carañana V, Urruticoechea A, Morales S, Bellet M, Antón A, Fernández-Abad M, Sánchez-Rovira P, Calabuig L, Pérez-Escuredo J, Sampayo-Cordero M, Cortés J, Llombart-Cussac A. Guerrero-Zotano Á, et al. ESMO Open. 2024 Sep 30;9(10):103733. doi: 10.1016/j.esmoop.2024.103733. Online ahead of print. ESMO Open. 2024. PMID: 39353215 Free PMC article. - Development of a nomogram to predict recurrence scores obtained using Oncotype DX in Japanese patients with breast cancer.
Shibata A, Tamura N, Kinowaki K, Nishikawa A, Tanaka K, Kobayashi Y, Ogura T, Tanabe Y, Kawabata H. Shibata A, et al. Breast Cancer. 2024 Nov;31(6):1018-1027. doi: 10.1007/s12282-024-01616-z. Epub 2024 Jul 17. Breast Cancer. 2024. PMID: 39020239 Free PMC article. - Impact of the OncotypeDX score and HER2 RNA PCR levels on HER2-low IHC levels in primary and metastasized tumors.
Feldman D, Sinberger LA, Salmon-Divon M, Ben-Dror J, Shachar SS, Sonnenblick A. Feldman D, et al. BMC Cancer. 2023 Oct 24;23(1):1031. doi: 10.1186/s12885-023-11530-w. BMC Cancer. 2023. PMID: 37875892 Free PMC article. - Recent Advances and Applications of Ambient Mass Spectrometry Imaging in Cancer Research: An Overview.
Kumar BS. Kumar BS. Mass Spectrom (Tokyo). 2023;12(1):A0129. doi: 10.5702/massspectrometry.A0129. Epub 2023 Sep 28. Mass Spectrom (Tokyo). 2023. PMID: 37789912 Free PMC article. Review. - Invasive breast carcinoma of no special type with medullary pattern: A case report at a tertiary facility in Tanzania.
Mremi A, Gnanamuttupulle M, Ntundu SH, Henke O, Chilonga K, Msuya D. Mremi A, et al. Clin Case Rep. 2023 Aug 22;11(8):e7844. doi: 10.1002/ccr3.7844. eCollection 2023 Aug. Clin Case Rep. 2023. PMID: 37621722 Free PMC article.
References
- Albain KS, et al. Prognostic and 286 predictive value of the 21-gene recurrence score assay in postmenopausal women with node-287 positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis 288 of a randomised trial. Lancet Oncol. 2010;11:55–65. doi: 10.1016/S1470-2045(09)70314-6. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous